We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
- Authors
Bendell, Johanna; Patel, Manish; Yoshida, Kenichiro; Seraj, Jabed; Weaver, Racquel; Lemech, Charlotte; Todaro, Thomas; Pant, Shubham; Arkenau, Hendrik-Tobias; Bendell, Johanna C; Patel, Manish R; Todaro, Thomas G
- Abstract
<bold>Purpose: </bold>TAS-102 is a novel oral agent combining the antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil (molar ratio 1:0.5). TAS-102 has shown good activity in refractory metastatic colorectal cancer with acceptable safety. No QT prolongation was seen in clinical studies. This study aimed to investigate TAS-102 cardiac safety for regulatory requirements.<bold>Methods: </bold>This was a phase 1, non-randomized study in adults with advanced solid tumors. Intensive QT assessments were conducted at baseline, placebo, and following single and multiple doses of TAS-102 during a 28-day cycle.<bold>Results: </bold>Following single- and multiple-dose administration (N = 30), the upper bounds of the one-sided 95 % confidence intervals for the difference between TAS-102 and placebo in time-matched baseline-subtracted 12-lead Holter QT intervals did not exceed 20 ms at any prespecified time point. One patient had a change from baseline in QTcI interval ≥60 ms, and one patient had a QTcI interval >500 ms following multiple-dose TAS-102 administration. No patient had an uncorrected QT, QTcF, or QTcB interval >500 ms. Based on the exposure-response analysis between TAS-102 plasma concentrations and the placebo-adjusted QTc intervals, none of the upper bounds of the one-sided 95 % prediction intervals exceeded 20 ms. There were no significant morphological changes for T or U waves. No cardiovascular AEs were reported in cycle 1. Across all cycles, no patient experienced an AE of ventricular tachycardia, ventricular fibrillation, syncope, or seizure.<bold>Conclusions: </bold>There was no clinically relevant relationship between TAS-102 plasma concentrations and QTc interval; TAS-102 had no clinically relevant effects on cardiac repolarization.<bold>Clinical Trials: </bold>ClinicalTrials.gov study number: NCT01867879.
- Subjects
COLON cancer treatment; COMBINATION drug therapy; ORAL medication; ANTINEOPLASTIC agents; THYMIDINE phosphorylase; CARDIOVASCULAR agents; MEDICATION safety; CLINICAL trials; AMBULATORY electrocardiography; CARDIOTOXICITY; COMPARATIVE studies; DRUG administration; ELECTROCARDIOGRAPHY; HEART; HETEROCYCLIC compounds; RESEARCH methodology; MEDICAL cooperation; ORAL drug administration; RESEARCH; TUMORS; EVALUATION research; DEOXYRIBONUCLEOSIDES; THERAPEUTICS
- Publication
Cancer Chemotherapy & Pharmacology, 2016, Vol 77, Issue 6, p1275
- ISSN
0344-5704
- Publication type
Academic Journal
- DOI
10.1007/s00280-016-3031-9